Overview
OncoRNA is developing next-generation personalized cancer immunotherapy using mRNA vaccine technology. The company was selected by the European Commission for the IPCEI Med4Cure project and aims to deliver personalized cancer immunotherapy batches within 3 weeks using synthetic DNA production methods.
Key people
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.